New therapies for treating Down syndrome require quality of life measurement
@article{Goodman2013NewTF, title={New therapies for treating Down syndrome require quality of life measurement}, author={M. Goodman and D. Brixner}, journal={American Journal of Medical Genetics Part A}, year={2013}, volume={161} }
Down syndrome (DS) is the most common genetic cause of cognitive deficits. Using mouse models and therapies for Alzheimer disease, researchers are exploring therapies that may improve cognitive function in people with DS. These developments shift the health economic paradigm of understanding DS from determining the appropriate screening tool to the effect of therapy on quality of life in those with DS. To date, there are no validated quality of life instruments for DS. Research should begin to… CONTINUE READING
Topics from this paper
7 Citations
Cost-effectiveness analysis for triple markers serum screening for Down's syndrome in Thai setting
- Medicine
- Indian journal of human genetics
- 2014
- 2
Vision problems in Down syndrome adults do not hamper communication, daily living skills and socialisation
- Medicine
- Wiener klinische Wochenschrift
- 2015
- 5
- PDF
Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children’s Oncology Group
- Medicine
- Journal of pediatric hematology/oncology
- 2017
- 9
Quality of health care according to people with Down syndrome, their parents and support staff—A qualitative exploration
- Psychology, Medicine
- Journal of applied research in intellectual disabilities : JARID
- 2019
- 4
- Highly Influenced
- PDF
References
SHOWING 1-10 OF 37 REFERENCES
Donepezil Significantly Improves Abilities in Daily Lives of Female down Syndrome Patients with Severe Cognitive Impairment: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
- Psychology, Medicine
- International journal of psychiatry in medicine
- 2011
- 42
Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24‐week open trial
- Medicine
- American journal of medical genetics. Part A
- 2003
- 50
Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
- Psychology, Medicine
- Journal of child and adolescent psychopharmacology
- 2006
- 37
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
- Psychology, Medicine
- Nature Neuroscience
- 2007
- 439
Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17
- Medicine
- American journal of medical genetics. Part A
- 2010
- 59
Effects of donepezil on cognitive functioning in Down syndrome.
- Psychology, Medicine
- American journal of mental retardation : AJMR
- 2003
- 48
Dramatic Improvement in down Syndrome—Associated Cognitive Impairment with Donepezil
- Medicine
- The Annals of pharmacotherapy
- 2005
- 16
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
- Medicine
- The Lancet
- 2012
- 133
Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series
- Medicine
- American journal of medical genetics. Part A
- 2007
- 40